More on ESAIY

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(OP:ESAIY)
Delayed: 7.53 -0.16 (2.08%)
Prev. Close $7.69  
Open$7.52 
52 Wk High$ 
52 Wk Low$ 
Day High$7.55 
Day Low$7.49 
P/E N/A  
EPS$ 
Volume77,000 

Friends, Peers and Foes (?): ESALF, EII BIIB (more...)

Mar 1, 2026 11:00 PM WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Ca
Feb 16, 2026 04:02 AM Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Feb 10, 2026 02:34 AM Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Feb 6, 2026 01:04 AM Eisai signs $388 million deal for cancer drug in Japan
Feb 6, 2026 01:04 AM Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Jan 25, 2026 11:52 PM FDA accepts Eisai's LEQEMBI IQLIK application for priority review
Jan 25, 2026 11:52 PM FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Jan 21, 2026 06:05 AM Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Jan 12, 2026 11:51 PM Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Jan 6, 2026 10:58 AM Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
View All Articles

Entities mentioned with ESAIY

View All Entities